Document is current
Any future updates will be listed below
-
Authors
Shankar, Archana https://orcid.org/0000-0003-3499-4309
Olender, Leonid
Hsu, Ian
Miyauchi, Masashi https://orcid.org/0000-0002-6301-3429
Pálovics, Róbert
Meaker, Grace A.
Kaito, Satoshi https://orcid.org/0000-0001-7966-291X
Rizq, Ola
Khoo, Hwei Minn
Bozhilov, Yavor
Igarashi, Kyomi J.
Bhadury, Joydeep https://orcid.org/0000-0002-4333-9974
Munson, Christy
Mack, Paul K.
Tan, Tze-Kai
Rehwinkel, Jan
Iwama, Atushi https://orcid.org/0000-0001-9410-8992
Wyss-Coray, Tony https://orcid.org/0000-0001-5893-0831
Nakauchi, Hiromitsu https://orcid.org/0000-0002-9841-6973
Haney, Michael S.
Wilkinson, Adam C. https://orcid.org/0000-0001-7406-0151
-
Funding
Funding for this research was provided by:
Kay Kendall Leukaemia Fund (KKL1378)
Wellcome Trust (302479Z23Z)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K99HL150218)
Leukemia and Lymphoma Society (3385-19)
European Hematology Association (RG-202211-02958)
- License Information
-
More Information
Article History
Received: 2 April 2025
Accepted: 23 December 2025
First Online: 23 January 2026
Competing interests
: H.N. is a co-founder of Celaid Therapeutics. A.C.W. is a consultant for ImmuneBRIDGE. However, none of these companies had input into the design, execution, interpretation, or publication of the work in this manuscript. No other authors declare competing interests.
